Biotech · Private company
OnKure, Inc.
Track this companyFree. Adds OnKure, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials31 recruiting or active
Pipeline programs8From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline8
- OKI-179 + binimetinibPhase 2 · RAS MutationClinicalTrials.gov · fetched Nov 12, 2026
- AtirmociclibPhase 1 · Advanced CancerClinicalTrials.gov · fetched Nov 12, 2026
- FulvestrantPhase 1 · Advanced CancerClinicalTrials.gov · fetched Nov 12, 2026
- OKI-179Phase 1 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- OKI-219Phase 1 · Advanced CancerClinicalTrials.gov · fetched Nov 12, 2026
- RibociclibPhase 1 · Advanced CancerClinicalTrials.gov · fetched Nov 12, 2026
- TrastuzumabPhase 1 · Advanced CancerClinicalTrials.gov · fetched Nov 12, 2026
- TucatinibPhase 1 · Advanced CancerClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials3
- First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast CancerPHASE1 · ACTIVE_NOT_RECRUITING · started Feb 26, 2024ClinicalTrials.gov NCT06239467 · fetched Nov 12, 2026
- NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)PHASE1_PHASE2 · COMPLETED · started May 11, 2022ClinicalTrials.gov NCT05340621 · fetched Nov 12, 2026
- A Study of OKI-179 in Patients With Solid TumorsPHASE1 · COMPLETED · started May 8, 2019ClinicalTrials.gov NCT03931681 · fetched Nov 12, 2026